Display options
Cite
Nakamura H, Jinzu H, Nagao K, et al. Plasma amino acid profiles are associated with insulin, C-peptide and adiponectin levels in type 2 diabetic patients. Nutr Diabetes. 2014;4:e133doi: 10.1038/nutd.2014.32.
Nakamura, H., Jinzu, H., Nagao, K., Noguchi, Y., Shimba, N., Miyano, H., Watanabe, T., & Iseki, K. (2014). Plasma amino acid profiles are associated with insulin, C-peptide and adiponectin levels in type 2 diabetic patients. Nutrition & diabetes, 4e133. https://doi.org/10.1038/nutd.2014.32
Nakamura, H, et al. "Plasma amino acid profiles are associated with insulin, C-peptide and adiponectin levels in type 2 diabetic patients." Nutrition & diabetes vol. 4 (2014): e133. doi: https://doi.org/10.1038/nutd.2014.32
Nakamura H, Jinzu H, Nagao K, Noguchi Y, Shimba N, Miyano H, Watanabe T, Iseki K. Plasma amino acid profiles are associated with insulin, C-peptide and adiponectin levels in type 2 diabetic patients. Nutr Diabetes. 2014 Sep 01;4:e133. doi: 10.1038/nutd.2014.32. PMID: 25177913; PMCID: PMC4183973.
Copy Download .nbib Format: NLM
Share it on

Nutr Diabetes. 2014 Sep 01;4:e133. doi: 10.1038/nutd.2014.32.

Plasma amino acid profiles are associated with insulin, C-peptide and adiponectin levels in type 2 diabetic patients.

Nutrition & diabetes

H Nakamura, H Jinzu, K Nagao, Y Noguchi, N Shimba, H Miyano, T Watanabe, K Iseki

Affiliations

  1. Institute for Innovation, Ajinomoto Co., Inc., Kawasaki, Japan.
  2. R&D Planning Department, Ajinomoto Co., Inc., Tokyo, Japan.
  3. Link and Communication Co., Inc., Tokyo, Japan.
  4. Iseki Internal Medicine, Tokyo, Japan.

PMID: 25177913 PMCID: PMC4183973 DOI: 10.1038/nutd.2014.32

Abstract

OBJECTIVES: Plasma-free amino acid (PFAA) profiles have been associated with a future risk of developing diabetes or cardiovascular disease in nondiabetic subjects. These PFAA alterations might predominantly result from the metabolic shift caused by insulin resistance and visceral fat deposition. The variety of PFAA profiles within diabetic subjects is not well researched. In this study, we focused on type 2 diabetic subjects and examined the association between PFAA profiles and insulin- and glucose-related variables.

METHODS: Fifty-one Japanese subjects diagnosed with type 2 diabetes were recruited from an outpatient clinic. The plasma concentrations of 21 amino acids; glucose-related markers including glucose, hemoglobin A1c (HbA1c), glycoalbumin and 1,5-anhydroglucitol; insulin-related markers including insulin, C-peptide, and the homeostasis model assessment of insulin resistance; and adipocytokines including adiponectin and leptin were determined. The association of PFAA and other metabolic profiles were analyzed, and stratified analyses of the PFAAs and clinical characteristics were performed according to the fasting plasma insulin and HbA1c levels. In addition, the PFAA indices that correlate to visceral fat obesity were evaluated.

RESULTS: Although strong correlations between PFAAs and glucose-related markers were not observed, several amino acids (branched-chain amino acids, tryptophan, alanine, tyrosine, glutamate and proline) and PFAA indices that evaluate visceral obesity were highly correlated with insulin-related markers and adiponectin (P<0.001). In the group of diabetic patients with hyperinsulinemia, the amino acid levels were significantly increased, which generally demonstrated good concordance with insulin-related markers and adiponectin levels.

CONCLUSIONS: The PFAA profiles in diabetic patients were strongly associated with hyperinsulinemia and hypoadiponectinemia, which might become risk evaluation factors for the development of cardiovascular diseases.

References

  1. Diabetes Res Clin Pract. 2004 Feb;63(2):135-42 - PubMed
  2. Diabetes Care. 2009 Sep;32(9):1678-83 - PubMed
  3. PLoS One. 2013 Sep 11;8(9):e73445 - PubMed
  4. PLoS One. 2011;6(9):e24143 - PubMed
  5. Circulation. 1998 Aug 4;98(5):398-404 - PubMed
  6. Clin Obes. 2012 Feb;2(1-2):29-40 - PubMed
  7. J Clin Invest. 2006 Jul;116(7):1784-92 - PubMed
  8. JAMA. 2009 Jul 8;302(2):179-88 - PubMed
  9. Obes Rev. 2010 Jan;11(1):11-8 - PubMed
  10. Diabetologia. 1985 Jul;28(7):412-9 - PubMed
  11. Am J Clin Nutr. 2010 Jan;91(1):258S-261S - PubMed
  12. JAMA. 2005 Jul 20;294(3):334-41 - PubMed
  13. Intern Med. 2010;49(8):721-7 - PubMed
  14. Am J Clin Nutr. 2006 Feb;83(2):513S-519S - PubMed
  15. Diabetes. 2013 Mar;62(3):743-52 - PubMed
  16. J Clin Invest. 1969 Dec;48(12):2273-82 - PubMed
  17. J Proteome Res. 2014 Jul 3;13(7):3455-66 - PubMed
  18. Cell Metab. 2009 Apr;9(4):311-26 - PubMed
  19. Diabetologia. 2010 Apr;53(4):757-67 - PubMed
  20. Expert Rev Mol Diagn. 2008 Jan;8(1):9-19 - PubMed
  21. Circulation. 2001 Dec 18;104(25):3052-6 - PubMed
  22. Rapid Commun Mass Spectrom. 2009 May;23(10):1483-92 - PubMed
  23. Am J Physiol Endocrinol Metab. 2013 Jun 1;304(11):E1175-87 - PubMed
  24. Nat Med. 2011 Apr;17(4):448-53 - PubMed
  25. PLoS Med. 2007 Aug;4(8):e263 - PubMed
  26. Eur Heart J. 2013 Jul;34(26):1982-9 - PubMed
  27. Diabetes Care. 1994 Feb;17(2):107-14 - PubMed
  28. Nat Med. 2001 Aug;7(8):941-6 - PubMed
  29. J Biol Chem. 2010 Apr 9;285(15):11348-56 - PubMed
  30. J Clin Invest. 1942 May;21(3):275-9 - PubMed
  31. Anal Chem. 2009 Jul 1;81(13):5172-9 - PubMed

Publication Types